CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants
CARB-X is awarding Peptilogics, headquartered in Pittsburgh, USA, up to US$2.56 million in non-dilutive funding to develop a new class of peptide antibiotics with broad activity against drug-resistant bacteria. The company could receive up to $9.61 million more in additional funding if the project achieves certain development milestones, for a potential total of up to $12.17 million.
The initial application of the new antibiotic would be towards serious infections associated with implants such as prosthetic knees and hips. CARB-X funding will support the development of Peptilogics’ lead compound PLG0206, including the filing of a US Food and Drug Administration (FDA) Investigational New Drug (IND) Application and Phase 1 clinical trial.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.